Menu

Country Focus

Italy

Others

Country Focus/Italy | Posted 25/05/2012

First posted: 25 May 2012 

The Italian pharmaceutical market is poorly developed* in the use of generic medicines.

France

Others

Country Focus/France | Posted 24/08/2012

First posted: 24 August 2012 

The French generics market is poorly developed* and is one of the smaller markets in Europe by both volume and value.

Germany

Others

Country Focus/Germany | Posted 14/10/2013

First posted: 14 October 2013 

Concerning biosimilars approved and marketed in Germany, view the following related articles:

Biosimilars approved and marketed in Germany

Germany wants to increase biosimilars penetration

Germany is already a mature (well-established) market* in the use of generic medicines.

Poland

Others

Country Focus/Poland | Posted 28/11/2013

First posted: 14 November 2013 

Poland is already a mature (well-established) market* in the use of generic medicines.

The Netherlands

Others

Country Focus/The Netherlands | Posted 30/11/2010

First posted: 12 August 2011 

Concerning biosimilars approved and marketed in The Netherlands, view the following related article:

Biosimilars approved and marketed in The Netherlands

The Netherlands is already a mature (well-established) market* in the use of generic medicines.

Belgium

Others

Country Focus/Belgium | Posted 25/05/2011

First posted: 12 August 2011 

Concerning biosimilars approved and marketed in Belgium, view the following related article:

Biosimilars approved and marketed in Belgium

The Belgian generics market is poorly developed* and is among the smallest in Europe by both volume and value.

United Kingdom

Policies and Legislation

Country Focus/United Kingdom | Posted 25/05/2011

First posted: 12 August 2011 

Concerning biosimilars policies in the UK, view the following related articles:

UK outlines process for developing biosimilars guidances

Biosimilar policies in the UK

In the UK generic pricing is regulated by the voluntary Pharmaceutical Price Regulation Scheme (PPRS), enabling free pricing.

Spain

Policies and Legislation

Country Focus/Spain | Posted 14/10/2011

First posted: 17 October 2011 

Concerning biosimilars policies in Spain, view the following related article:

Biosimilar policies in Spain

Spain does not have a coherent generic medicines policy and there is no generic medicines competition within the existing regulatory frameworks [1].

Denmark

Policies and Legislation

Country Focus/Denmark | Posted 09/12/2011

First posted: 6 December 2011 

View the article below to learn of measures to change prescribing patterns of angiotensin receptor blockers:

Impact of delisting ARBs in Denmark

Portugal

Policies and Legislation

Country Focus/Portugal | Posted 15/03/2012

First posted: 15 March 2012 

Portugal does not have a coherent generic medicines policy and there is no generic medicines competition within the existing regulatory frameworks [1].